|
Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
妊娠中にラコサミドを使用し，健児を得た一症例
| Title: | 妊娠中にラコサミドを使用し，健児を得た一症例 |
| Other Titles: | Case Report on a Woman with Epilepsy Who Took Lacosamide during Pregnancy and Gave Birth to a Healthy Infant |
| Authors: | Kitamura, Seika Browse this author | | Nishimura, Ayako Browse this author | | Takekuma, Yoh Browse this author →KAKEN DB | | Saito, Yoshitaka Browse this author →KAKEN DB | | Umazume, Takeshi Browse this author →KAKEN DB | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | lacosamide | | pregnancy | | epilepsy | | teratogenicity |
| Issue Date: | 1-Sep-2022 |
| Publisher: | The Pharmaceutical Society of Japan |
| Journal Title: | Yakugaku zasshi |
| Journal Title(alt): | 薬学雑誌 | | Journal of the pharmaceutical society of Japan |
| Volume: | 142 |
| Issue: | 9 |
| Start Page: | 1031 |
| End Page: | 1035 |
| Publisher DOI: | 10.1248/yakushi.22-00044 |
| Abstract: | Lacosamide is a novel antiepileptic drug. Although many antiepileptic drugs reportedly pose a risk to fetuses, patients with epilepsy are advised to continue their medications during pregnancy. There have been few reports on lacosamide use during pregnancy, and its effects on the fetus remain unclear. Here, we report a case of lacosamide use during pregnancy. The 33-year-old patient was treated with oral lacosamide (400 mg/d) for symptomatic partial epilepsy. She was concomitantly treated with folic acid (5 mg/d) beginning 4 days before her last menstrual cycle. She was also concomitantly treated with oral perampanel (2 mg/d) at 5-7 weeks' gestation for seizure control but discontinued perampanel after the pregnancy was discovered. She progressed through her pregnancy with only mild seizures. Fetal growth was normal and ultrasonography revealed no external malformations. The patient had an elective cesarean section at 37 weeks and 2 days owing to a previous post-cesarean pregnancy. Her baby boy weighed 3025 g; his Apgar score was 8 and 9, 1 and 5 min, respectively, and his umbilical artery blood pH was 7.348. He had no congenital anomalies and no neonatal drug withdrawal symptoms. This suggests that lacosamide may have a low risk of teratogenicity and fetal toxicity. Thus, this case is valuable for clinicians who are considering the administration of antiepileptic drugs during pregnancy. In the future, more reports on the use of lacosamide during pregnancy should be collected. |
| Rights: | Copyright 2022 The Pharmaceutical Society of Japan |
| Type: | article |
| URI: | http://hdl.handle.net/2115/87164 |
| Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
